Becton, Dickinson and Company (BDX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Thomas E. Polen Jr. | President, CEO & Chairman | 3.46M | -- | 1973 |
| Mr. Christopher J. DelOrefice | Executive VP & CFO | 1.6M | -- | 1972 |
| Ms. Shana Carol Neal | Executive VP & Chief People Officer | 1.79M | -- | 1966 |
| Mr. David B. Hickey | Executive VP & President of Life Sciences Segment | 1.11M | 562.03k | 1964 |
| Mr. Michael Garrison | Executive VP & President of Medical segment | 1.73M | -- | 1970 |
| Mr. Thomas J. Spoerel | Senior VP, Controller & Chief Accounting Officer | -- | -- | 1979 |
| Ms. Elizabeth McCombs | Executive VP & Chief Technology Officer | -- | -- | 1976 |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board | -- | -- | -- |
| Ms. Denise Russell Fleming | Executive VP of Technology & Global Services and Chief Information Officer | -- | -- | 1970 |
| Mr. Greg Rodetis | Head of Investor Relations | -- | -- | -- |
Becton, Dickinson and Company
- Sector:
- Healthcare
- Industry: Medical Instruments & Supplies
- Full Time Employees:
- 73,000
Description
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Corporate Governance
Recent Events
- Mar 29, 2024Dividend Date
- Mar 07, 2024Ex-Dividend Date
- Feb 27, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 16, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Feb 14, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing